Kura Oncology, Inc. (NASDAQ: KURA) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
Latest market price
11.73
+0.01+0.09%
TA
Loading chart...
Snapshot
| Index | - | P/E | - | EPS (ttm) | -3.37 | Insider Own | 11.51% | Shs Outstand | 88.77M | Perf Week | 2.99% |
| Market Cap | 1.04B | Forward P/E | - | EPS next Y | -2.37 | Insider Trans | 0.63% | Shs Float | 86.00M | Perf Month | -6.38% |
| Enterprise Value | 545.32M | PEG | - | EPS next Q | -0.84 | Inst Own | - | Short Float | 15.60% | Perf Quarter | 18.13% |
| Income | -296.00M | P/S | 13.52 | EPS this Y | 4.44% | Inst Trans | - | Short Ratio | 7.29 | Perf Half Y | 39.15% |
| Sales | 77.00M | P/B | 21.69 | EPS next Y | 26.31% | ROA | -50.49% | Short Interest | 13.42M | Perf YTD | 12.90% |
| Book/sh | 0.54 | P/C | 2.01 | EPS next 5Y | - | ROE | -207.18% | 52W High | 13.90 -15.61% | Perf Year | 44.99% |
| Cash/sh | 5.85 | P/FCF | - | EPS past 3/5Y | - | ROIC | -66.95% | 52W Low | 7.36 59.38% | Perf 3Y | 20.31% |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | - | Gross Margin | 94.73% | Volatility | 4.20% 4.78% | Perf 5Y | -43.33% |
| Dividend TTM | - | EV/Sales | 7.08 | EPS Y/Y TTM | -66.83% | Oper. Margin | -411.90% | ATR (14) | 0.60 | Perf 10Y | 83.57% |
| Dividend Ex-Date | - | Quick Ratio | 4.71 | Sales Y/Y TTM | 42.59% | Profit Margin | -384.30% | RSI (14) | 49.64 | Recom | 2.12 |
| Dividend Gr. 3/5Y | - | Current Ratio | 4.73 | EPS Q/Q | -2.67% | SMA20 | -4.99% | Beta | 0.45 | Target Price | 23.88 |
| Payout | 0.00% | Debt/Eq | 0.11 | Sales Q/Q | 40.00% | SMA50 | 5.02% | Rel Volume | 1.46 | Prev Close | 11.72 |
| Employees | 260 | LT Debt/Eq | 0.11 | Earnings | Nov 03 | SMA200 | 19.50% | Avg Volume | 1.82M | Price | 11.73 |
| IPO Date | Sep 16, 2015 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 12.23% 3.53% | Net Debt/EBITDA | 0.16 | Volume | 2,664,379 | Change | 0.09% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Aug-24-26 | Reiterated | Raymond James | $24 | |
| Aug-24-26 | Reiterated | Morgan Stanley | $24 | |
| Jun-15-26 | Reiterated | Bernstein | $24 | |
| Jun-04-26 | Reiterated | CLSA | $24 | |
| Jun-04-26 | Reiterated | Wells Fargo | $24 | |
| May-28-26 | Reiterated | Oppenheimer | Outperform | $24 |
| May-28-26 | Reiterated | Jefferies | Buy | $24 |
| Apr-14-26 | Initiated | Lake Street | Buy | $23 |
| Mar-13-26 | Reiterated | UBS | Buy | $14 → $15 |
| Jan-13-26 | Reiterated | Leerink Partners | Outperform | $20 |
Latest News· Times ET
Sep-17-26
Sep-16-26
Sep-16-2609:51AM
Sep-09-26
03:00AM
Sep-08-26
Sep-04-26
Sep-04-2603:30AM
Sep-02-26
Sep-01-26
03:15AM
Aug-31-26
Aug-27-26
Aug-26-26
Aug-26-2610:16AM
Aug-25-26
Aug-25-2607:57AM
07:14AM
04:06AM
Company
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 77 | 67 | 54 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 4 | 0 | 0 | — | — | — | — | — | — | |
| Gross Profit | 74 | 67 | 54 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 135 | 120 | 77 | — | — | — | — | — | — | |
| Research and Development | 259 | 251 | 170 | — | — | — | — | — | — | |
| Other Operating Expense | -2 | 0 | 0 | — | — | — | — | — | — | |
| Operating Income | -318 | -304 | -193 | — | — | — | — | — | — | |
| Interest Expense | 0 | 2 | 2 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 23 | 27 | 23 | — | — | — | — | — | — | |
| Net Income Before Taxes | -296 | -278 | -172 | — | — | — | — | — | — | |
| Income Taxes | 0 | 0 | 2 | — | — | — | — | — | — | |
| Consolidated Net Income | -296 | -279 | -174 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | -296 | -279 | -174 | — | — | — | — | — | — | |
| Net Income | -296 | -279 | -174 | — | — | — | — | — | — | |
| EPS (Recurring) | -3.37 | -3.18 | -2.02 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -3.37 | -3.18 | -2.02 | — | — | — | — | — | — | |
| EPS (Diluted) | -3.37 | -3.18 | -2.02 | — | — | — | — | — | — | |
| EBITDA | -293 | -276 | -169 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 13.56 | 13.65 | 13.87 | — | — | — | — | — | — | |
| Gross Margin | 96.10 | 100.00 | 100.00 | — | — | — | — | — | — | |
| Operating Margin | -412.99 | -453.73 | -357.41 | — | — | — | — | — | — | |
| Net Margin | -384.42 | -416.42 | -322.22 | — | — | — | — | — | — | |
| Shares Outstanding | 89 | 88 | 86 | — | — | — | — | — | — | |
| Market Capitalization | 1,044 | 914 | 749 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| WILSON TROY EDWARD | President and CEO | Aug 24 '26 | Buy | 12.39 | 100,000 | 1,239,000 | 479,194 | Aug 24 |
| Powl Brian T. | Chief Commercial Officer | Aug 21 '26 | Sale | 11.89 | 4,345 | 51,663 | 169,269 | Aug 24 |
| Bair Teresa Brophy | Chief Legal Officer | Aug 19 '26 | Sale | 12.63 | 31,487 | 397,681 | 195,444 | Aug 21 |
| WILSON TROY EDWARD | President and CEO | Aug 17 '26 | Buy | 11.12 | 100,000 | 1,112,000 | 379,194 | Aug 17 |
| Leoni Mollie | Chief Medical Officer | Jun 18 '26 | Sale | 9.82 | 84,929 | 834,283 | 182,345 | Jun 22 |
| Powl Brian T. | Chief Commercial Officer | May 21 '26 | Sale | 11.00 | 10,000 | 110,000 | 173,614 | May 22 |
| Powl Brian T. | Chief Commercial Officer | May 19 '26 | Sale | 9.21 | 339 | 3,122 | 183,614 | May 20 |
| FORD KATHLEEN | Chief Operating Officer | May 19 '26 | Sale | 9.08 | 2,257 | 20,483 | 153,560 | May 20 |
| Bair Teresa Brophy | Chief Legal Officer | May 18 '26 | Sale | 9.38 | 2,256 | 21,160 | 226,931 | May 20 |
| WILSON TROY EDWARD | President and CEO | Mar 23 '26 | Option Exercise | 6.15 | 12,206 | 75,066 | 435,456 | Mar 25 |
| Malley Thomas | Director | Mar 18 '26 | Option Exercise | 3.12 | 20,000 | 62,400 | 10,000 | Mar 20 |
| Powl Brian T. | Chief Commercial Officer | Jan 27 '26 | Sale | 8.46 | 6,414 | 54,266 | 183,275 | Jan 27 |
| FORD KATHLEEN | Chief Operating Officer | Jan 27 '26 | Sale | 8.46 | 1,813 | 15,339 | 153,560 | Jan 27 |
| Leoni Mollie | Chief Medical Officer | Jan 27 '26 | Sale | 8.46 | 8,180 | 69,209 | 267,274 | Jan 27 |
| DOYLE THOMAS JAMES | SVP, Finance & Accounting | Jan 27 '26 | Sale | 8.46 | 7,142 | 60,427 | 145,167 | Jan 27 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.